{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:02Z","timestamp":1791925322793,"version":"4.3.4"},"reference-count":10,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,6,30]]},"DOI":"10.5582\/ddt.2022.01038","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T22:12:05Z","timestamp":1656108725000},"page":"142-144","source":"Crossref","is-referenced-by-count":3,"title":["Safety of linezolid, rifampicin, and clindamycin combination therapy in patients with prosthetic joint infection"],"prefix":"10.5582","volume":"16","author":[{"given":"Shunsuke","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nissan Tamagawa Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ariza J, Cobo J, Baraia-Etxaburu J, <i>et al<\/i>. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin. 2017; 35:189-195.","DOI":"10.1016\/j.eimc.2016.08.012"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sendi P, Zimmerli W. Antimicrobial treatment concepts for orthopaedic device-related infection. Clin Microbiol Infect. 2012; 18:1176-1184.","DOI":"10.1111\/1469-0691.12003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Leijtens B, Elbers JBW, Sturm PD, Kullberg BJ, Schreurs BW. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: A retrospective observational study. BMC Infect Dis. 2017; 17:321.","DOI":"10.1186\/s12879-017-2429-2"},{"key":"4","unstructured":"4. Food and Drug Administration. ZYVOX<sup>\u00ae<\/sup>: Highlights of prescribing information. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021131s040lbl.pdf<\/i> (accessed December 15, 2021)."},{"key":"5","unstructured":"5. Electronic Medicines Compendium (EMC), clindamycin 600 mg\/50 ml solution for infusion - Summary of product characteristics (SmPC) - (emc). (2021c). <i>https:\/\/www<\/i><i>.<\/i><i>medicines.org.uk\/emc\/product\/11007<\/i> (accessed December 15, 2021)."},{"key":"6","unstructured":"6. Electronic Medicines Compendium (EMC), Dalacin C Capsules 150 mg - Summary of product characteristics (SmPC) - (emc). (2021b). <i>https:\/\/www.medicines.org.uk\/emc\/product\/1210<\/i> (accessed December, 15 2021)."},{"key":"7","unstructured":"7. Electronic Medicines Compendium (EMC), Rifadin 150 mg Capsules - Summary of product characteristics (SmPC) - (emc). (2021a). <i>https:\/\/www.medicines.org.uk\/emc\/product\/6382\/smpc<\/i> (accessed December 15, 2021)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, Damle B. Unexpected effect of rifampin on the pharmacokinetics of linezolid: <i>In silico<\/i> and <i>in vitro<\/i> approaches to explain its mechanism. J Clin Pharmacol. 2011; 51:229-236.","DOI":"10.1177\/0091270010366445"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Join-Lambert O, Ribadeau-Dumas F, Jullien V, Kitzis MD, Jais JP, Coignard-Biehler H, Guet-Revillet H, Consigny PH, Delage M, Nassif X, Lortholary O, Nassif A. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. Eur J Dermatol. 2014; 24:94-95.","DOI":"10.1684\/ejd.2013.2213"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tanaka R, Suzuki Y, Takumi Y, Iwao M, Sato Y, Hashinaga K, Hiramatsu K, Kadota JI, Itoh H. A retrospective analysis of risk factors for linezolid-associated hyponatremia in Japanese patients. Biol Pharm Bull. 2016; 39:1968-1973.","DOI":"10.1248\/bpb.b16-00418"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/3\/16_2022.01038\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T04:47:59Z","timestamp":1658551679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/3\/16_2022.01038\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01038","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"2022.01038"}}